WBA · Walgreens Boots Alliance, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Annual Quarterly

Income Statement

Line item	Q3 '25	Q2 '25	Q1 '25	Q3 '24	Q2 '24	Q1 '24	Q3 '23	Q2 '23	Q1 '23	Q3 '22
Revenue	$38.99B	$38.59B	$39.46B	$36.35B	$37.05B	$36.71B	$35.41B	$34.86B	$33.38B	$32.60B
Cost of Revenue	$32.48B	$31.65B	$32.68B	$29.89B	$30.01B	$29.94B	$28.83B	$27.81B	$26.43B	$26.02B
Gross Profit	$6.51B	$6.93B	$6.78B	$6.46B	$7.04B	$6.77B	$6.59B	$7.05B	$6.95B	$6.57B
R&D	-	-	-	-	-	-	-	-	-	-
SG&A	$6.49B	$8.89B	$7.01B	$6.39B	$7.92B	$6.85B	$7.12B	$6.93B	$13.16B	$7.02B
Total Operating Expenses	-	-	-	-	-	-	-	-	-	-
D&A	$359.00M	$357.00M	$625.00M	$369.00M	$374.00M	$616.00M	$372.00M	$361.00M	$495.00M	$331.00M
Operating Income	$53.00M	($5.57B)	($245.00M)	$111.00M	($13.17B)	($39.00M)	($477.00M)	$197.00M	($6.15B)	($320.00M)
Interest Expense	$126.00M	$129.00M	$122.00M	$113.00M	$138.00M	$99.00M	$173.00M	$141.00M	$110.00M	$108.00M
Income Tax	$126.00M	($212.00M)	$66.00M	$20.00M	($782.00M)	($74.00M)	($330.00M)	$70.00M	($1.45B)	($242.00M)
Net Income	($175.00M)	($2.85B)	($265.00M)	$344.00M	($5.91B)	($67.00M)	$118.00M	$703.00M	($3.72B)	$289.00M
EPS - Basic	($0.20)	($3.30)	($0.31)	$0.40	($6.85)	($0.08)	$0.14	$0.81	($4.31)	$0.33
EPS - Diluted	($0.20)	($3.30)	($0.31)	$0.40	($6.85)	($0.08)	$0.14	$0.81	($4.31)	$0.33

Balance Sheet

Line item	Q3 '25	Q2 '25	Q1 '25	Q3 '24	Q2 '24	Q1 '24	Q3 '23	Q2 '23	Q1 '23	Q3 '22
Cash & Equivalents	$766.00M	$702.00M	$859.00M	$1.32B	$668.00M	$784.00M	$728.00M	$1.09B	$2.35B	$1.36B
Accounts Receivable	$6.55B	$5.94B	$6.19B	$5.85B	$6.20B	$5.97B	$5.38B	$5.73B	$4.85B	$5.02B
Inventory	$7.32B	$7.84B	$9.12B	$8.32B	$8.56B	$9.45B	$8.26B	$8.76B	$9.32B	$8.35B
Accounts Payable	$13.62B	$13.35B	$14.55B	$14.08B	$12.78B	$13.59B	$12.63B	$12.72B	$12.18B	$11.26B
Current Assets	$15.70B	$16.24B	$17.48B	$18.34B	$16.56B	$17.34B	$15.50B	$17.69B	$19.52B	$16.90B
Total Assets	$69.41B	$70.22B	$78.54B	$81.04B	$84.21B	$97.82B	$96.63B	$100.48B	$92.88B	$90.12B
Current Liabilities	$25.96B	$26.59B	$27.45B	$26.95B	$24.91B	$26.12B	$24.54B	$28.23B	$28.04B	$22.58B
Long-term Debt	$6.94B	$6.61B	$7.61B	$8.04B	$7.54B	$7.58B	$8.14B	$8.82B	$7.79B	$10.62B
Total Liabilities	$62.09B	$62.96B	$67.27B	$68.86B	$68.84B	$70.07B	$68.14B	$70.88B	$68.14B	$59.72B
Stockholders' Equity	$7.18B	$7.11B	$9.94B	$10.45B	$13.48B	$19.48B	$20.02B	$21.19B	$20.58B	$25.27B
Retained Earnings	$19.83B	$20.01B	$22.86B	$23.35B	$26.45B	$32.57B	$33.06B	$33.95B	$33.66B	$37.80B

Cash Flow

Line item	Q3 '25	Q2 '25	Q1 '25	Q3 '24	Q2 '24	Q1 '24	Q3 '23	Q2 '23	Q1 '23	Q3 '22
Operating Cash Flow	-	-	($140.00M)	-	-	($281.00M)	-	-	$493.00M	-
Investing Cash Flow	-	-	($76.00M)	-	-	$85.00M	-	-	$1.86B	-
Financing Cash Flow	-	-	($1.69B)	-	-	$186.00M	-	-	($599.00M)	-
CapEx	-	-	$284.00M	-	-	$506.00M	-	-	$610.00M	-
Free Cash Flow	-	-	($424.00M)	-	-	($787.00M)	-	-	($117.00M)	-

Ratios

Metric	Q3 '25	Q2 '25	Q1 '25	Q3 '24	Q2 '24	Q1 '24	Q3 '23	Q2 '23	Q1 '23	Q3 '22
Profitability
Gross margin	16.7%	18.0%	17.2%	17.8%	19.0%	18.4%	18.6%	20.2%	20.8%	20.2%
Operating margin	0.1%	-14.4%	-0.6%	0.3%	-35.5%	-0.1%	-1.3%	0.6%	-18.4%	-1.0%
EBITDA margin	1.1%	-13.5%	1.0%	1.3%	-34.5%	1.6%	-0.3%	1.6%	-16.9%	0.0%
Net margin	-0.4%	-7.4%	-0.7%	0.9%	-15.9%	-0.2%	0.3%	2.0%	-11.1%	0.9%
Free cash flow margin	-	-	-1.1%	-	-	-2.1%	-	-	-0.4%	-
FCF / Net income	-	-	1.60	-	-	11.75	-	-	0.03	-
R&D / Revenue	-	-	-	-	-	-	-	-	-	-
SG&A / Revenue	16.7%	23.0%	17.8%	17.6%	21.4%	18.7%	20.1%	19.9%	39.4%	21.5%
Effective tax rate	-	-	-	5.5%	-	-	-	9.1%	-	-514.9%
Return on assets	-0.3%	-4.1%	-0.3%	0.4%	-7.0%	-0.1%	0.1%	0.7%	-4.0%	0.3%
Return on equity	-2.4%	-40.1%	-2.7%	3.3%	-43.8%	-0.3%	0.6%	3.3%	-18.1%	1.1%
Return on invested capital	0.3%	-32.1%	-1.1%	0.6%	-49.5%	-0.1%	-1.3%	0.6%	-17.1%	-0.9%
Liquidity
Current ratio	0.60	0.61	0.64	0.68	0.66	0.66	0.63	0.63	0.70	0.75
Quick ratio	0.32	0.32	0.30	0.37	0.32	0.30	0.30	0.32	0.36	0.38
Cash ratio	0.03	0.03	0.03	0.05	0.03	0.03	0.03	0.04	0.08	0.06
Leverage
Debt / Equity	0.97	0.93	0.77	0.77	0.56	0.39	0.41	0.42	0.38	0.42
Debt / Assets	0.10	0.09	0.10	0.10	0.09	0.08	0.08	0.09	0.08	0.12
Debt / EBITDA	16.84	-	20.03	16.76	-	13.15	-	15.81	-	965.00
Interest coverage	0.4x	-43.2x	-2.0x	1.0x	-95.4x	-0.4x	-2.8x	1.4x	-55.9x	-3.0x
Equity multiplier	9.66	9.88	7.90	7.76	6.24	5.02	4.83	4.74	4.51	3.57
Liabilities / Assets	0.89	0.90	0.86	0.85	0.82	0.72	0.71	0.71	0.73	0.66
Efficiency
Asset turnover	0.56	0.55	0.50	0.45	0.44	0.38	0.37	0.35	0.36	0.36
Inventory turnover	4.44	4.03	3.58	3.59	3.51	3.17	3.49	3.18	2.84	3.12
Days sales outstanding	61d	56d	57d	59d	61d	59d	55d	60d	53d	56d
Days inventory outstanding	82d	90d	102d	102d	104d	115d	105d	115d	129d	117d
Days payable outstanding	153d	154d	163d	172d	155d	166d	160d	167d	168d	158d
Cash conversion cycle	-9d	-7d	-3d	-12d	10d	9d	0d	8d	14d	15d
Valuation
P / E	-	-	-	-	-	-	-	-	-	-
P / B	-	-	-	-	-	-	-	-	-	-
P / S	-	-	-	-	-	-	-	-	-	-
EV / EBITDA	-	-	-	-	-	-	-	-	-	-
Growth
Revenue growth (YoY)	7.2%	4.1%	7.5%	2.6%	6.3%	10.0%	8.6%	3.3%	-1.5%	-4.2%
Revenue CAGR (3y)	6.1%	4.6%	5.2%	2.2%	4.2%	0.4%	0.7%	-0.9%	-0.9%	-1.7%
Revenue CAGR (5y)	2.4%	1.5%	2.8%	1.1%	-	3.6%	0.6%	1.1%	1.7%	1.6%
Gross profit growth (YoY)	0.7%	-1.5%	0.1%	-1.9%	-0.2%	-2.6%	0.2%	-8.5%	-8.2%	-8.1%
Operating income growth (YoY)	-52.3%	57.7%	-528.2%	-	-	99.4%	-49.1%	-84.2%	-	-
Net income growth (YoY)	-	51.7%	-295.5%	191.5%	-	98.2%	-59.2%	-20.4%	-	-75.9%
EPS growth (YoY)	-	51.8%	-287.5%	185.7%	-	98.1%	-57.6%	-20.6%	-	-76.1%
EPS CAGR (3y)	-	-	-	-33.8%	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-	-	-	-	-
FCF growth (YoY)	-	-	46.1%	-	-	-572.6%	-	-	-	-
FCF CAGR (5y)	-	-	-	-	-	-	-	-	-	-
Book value growth (YoY)	-31.2%	-47.3%	-49.0%	-47.8%	-36.4%	-5.3%	-20.8%	-20.6%	-21.7%	7.9%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2024-08-31.

Business segments

$147.68B total

United States Retail Pharmacy Segment$115.78B · 78.4%

International Reportable Segment$23.55B · 15.9%

USHealthcare$8.35B · 5.7%

Product / service

$127.84B total

Pharmacy$88.87B · 69.5%

Retail$26.91B · 21.0%

Pharmaceutical Wholesale$12.07B · 9.4%

Geographic

$147.66B total

US$124.18B · 84.1%

DE$12.07B · 8.2%

GB$9.55B · 6.5%

Other$1.86B · 1.3%

Peer comparison

Same SIC group: Retail-Drug Stores and Proprietary Stores

Company	Revenue (last FY)	Net margin	ROE
CVS	$402.07B	0.4%	2.4%
GRDN	$1.23B	-9.0%	-50.5%
PETS	$274.10M	-2.3%	-7.4%
MDVL	$43.11M	-110.5%	-228.7%
CVET	$4.58B	-1.2%	-3.6%

Comparing Walgreens Boots Alliance against the 5 most active filers in the same SIC group.